Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Cancer cell or component thereof
Reexamination Certificate
2006-06-13
2006-06-13
Rawlings, Stephen L. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Cancer cell or component thereof
C424S185100, C424S192100, C424S193100, C514S002600, C514S013800, C530S300000, C530S325000
Reexamination Certificate
active
07060284
ABSTRACT:
Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.
REFERENCES:
patent: 5601989 (1997-02-01), Cheever et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5773230 (1998-06-01), Cheever et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6075122 (2000-06-01), Cheever et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 2003/0170235 (2003-09-01), Cohen
patent: 2004/0037823 (2004-02-01), Paton et al.
patent: 94/07531 (1994-04-01), None
patent: 97/38011 (1997-10-01), None
patent: WO 98/17797 (1998-04-01), None
Harwerth IM, et al. Br J Cancer. Dec. 1993; 68 (6): 1140-5.
Skolnick J, et al. Trends Biotechnol. Jan. 2000; 18 (1): 34-9.
Kyngas J, et al. Protein Eng. 1998; 11 (5): 345-8.
Pal D, et al. Acta Crystallogr D Biol Crystallogr. May 2000; 56 ( Pt 5): 589-94.
Street AG, et al. Proc Natl Acad Sci U S A. Aug. 3, 1999;96 (16): 9074-6.
Bowie et al. Science. Mar. 16, 1990; 247 (4948): 1306-10.
Sotiriadou R, et al. Br J cancer. 2001; 85 (10): 1527-34.
Schirle M, et al. J Immunol Methods. 2001; 257: 1-16.
Salazar LG, et al. Clin. Cancer Res. Nov. 15, 2003; 9 (15): 5559-65.
Partidos et al. (Mol. Immunol. Nov.-Dec. 1997; 34 (16-17): 1105-1111).
Lairmore et al. (J. Virol. Oct. 1995; 69 (10): 6077-6089).
Abstract P752, “Peptide Vaccine Strategies for Immunotherapy of HER-2/NEU Overexpressing Cancers” by Dakappagari, et al., 16thAmerican Peptide Symposium, Jun. 26-Jul. 1, 1999, Minneapolis, Minnesota.
Abstarct P442, “Biological Effects of Peptide Antibodies Raised to HER-2
eu. Implications for Therapy of Human Breast Cancer” by Woodbine, et al., The 1997 American Peptide Symposium, Jun. 14-19, 1997, Nashville, Tennessee.
Abstract MS009, “Peptide Vaccine Strategy for Immunotherapy of Human Breast Cancer Using HER-2
eu Oncogene” by Woodbine, et al., Fourteenth American peptide Symposium, Jun. 18-23, 1995, Columbus, Ohio.
“Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine” by Dakappagari, et al.,Cancer Research, 60, 3782-3789, Jul. 15, 2000.
““De Novo” Engineering of Peptide Immunogenic and Antigenic Determinants as Potential Vaccines” by Kaumaya, et al.,Peptides: Design, Synthesis and Biological Activity,Channa Basava and G.M. Anantharamaiah Editors, 1994,Birkāuser Boston.
Abstract P751 “The Immunogenicity of Peptide Versus DNA Vaccine of an HER-2 CTL Epitope for Breast and Ovarian Cancers” by Jiang, et al., 16thAmerican Peptide Symposium, Jun. 26-Jul. 1, 1999, Minneapolis, Minnesota.
“Evaluation of the immunogenicity of peptide and DNA constructs for HER-2
eu epitopes” by Jiang, et al.,Peptides for the New Millennium, (Eds. Fields, G.B., Tam, T.P., and Barany), Kluwer Academic Publisher, Dordrecth, Netherlands, 2000, pp. 695-696.
“Evaluation of Chimeric B-Cell Epitope of HER-2: Application to Cancer Patients” Dissertation by Naveen K. Dakappagari, M.S., The Ohio State University, Submitted Jun. 1, 2001.
“Biological Effects of Anti-Peptide Antibodies Against HER-2/NEU Receptor Tyrosine Kinase: Implications for Therapy of Human Breast Cancer” Dissertation by Donna-Beth Woodbine, B.S., The Ohio State University, Submitted 1997, Published Aug. 5, 1998.
Supplementary European Search Reportdated Aug. 10, 2004.
“Peptide Vaccines Incorporating a “Promiscuous” T-cell Epitope bypass Certain Haplotype Restricted Immune Responses and Provide Broad Spectrum Immunogenicity” by Kaumaya, et al.,Journal of Molecular Recognition, vol. 6, 81-94 (1993).
“Human T-Lymphotrophic Virus Type 1 Peptides in Chimeric and Multivalent Constructs with Promiscuous T-Cell Epitopes Enhance Immunogenicity and Overcome Genetic Restriction” by Lairmore, et al.,Journal of Virology, Oct. 1995, vol. 69, No. 10, p. 6077-6089.
“Subunit Peptide Cancer Vaccines Targeting Activating Mutations of the p21RASProto-Oncogene” by Triozai, et al.,Biomedical Peptides, Proteins and Nucleic Acids, vol. 1, 185-192 (1995).
“Granulocyte-Macrophage Colony Stimulating Factor: An effective Adjuvant for Protein and Peptide-Based Vaccines” by Disis, et al.,Blood, vol. 88, No. 1, Jul. 1, 1996, p. 202-210.
“Identification of HER2
eu-Derived Peptide Epitopes Recognized by Gastric Cancer-Specific Cytotoxic T Lymphocytes” by Kono, et al.,Int. J. Cancer, 78, 202-208 (1998).
“Identification of HLA-A3-restricted Cytotoxic T Lymphocyte Epitopes from Carcinoembryonic Antigen and HER-2
eu by Primaryin VitroImmunization with Peptide-pulsed Dendritic Cells” by Kawashima, et al.,Cancer Research, 59, 431-435, Jan. 15, 1999.
“Immunization to Oncogenic HER-2
eu Protein with Peptide Based Vaccines” by Disis, et al., Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, New York, vol. 36, Mar. 1995, p. 251.
“T-Cell, Adhesion, and B-Cell Epitopes of the Cell SurfaceStreptococcus mutansProtein Antigen I/II” by Kelly, et al.,Infection and Immunity, vol. 63, No. 9, Sep. 1995, p. 3649-3658.
“Antigenicity and immunogenicity of multiple antigen peptides (MAP) containingP. vivaxCS epitopes inAotusmonkeys” by Herrera, et al.,Parasite Immunology, 1997: 19: 161-170.
“A novel human HER2-derived peptide homologous to the mouse Kd-restricted tumor rejection antigen can induce HLA-A24-restricted cytotoxic T lymphyocytes in ovarian cancer patients and healthy individuals” by Okugawa, et al.,Eur. J. Immunol, 2000, 30:3338-3346.
“A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses” by Dakappagari, et al.,The Journal of Immunology, Apr. 15, 2003, vol. 170, No. 8, p. 4242-4253.
“Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide” by Frangione-Beebe, et al.,Vaccine, 19 (2001) 1068-1081.
Abstract P1004, “A Combination of HER-2 Peptide Epitope Vaccines Mediate Superior Biological Effects” by Kaumaya et al., Second International and the Seventeenth American Peptide Symposium, Jun. 9-14, 2001, San Diego, CA, attached to pages identifying the Source Publication.
Abstract P1012, “Evaluation of synergistic Interaction Between Cytokines and Peptide Epitope Vaccines in Protection Against HER-2 Expressing Lung Metastases” by Dakappagari et al., Second International and the Seventeenth American Peptide Sympsoium, Jun. 9-14, 2001, San Diego, CA, attached to pages identifying the Source Publication.
Kaumaya Pravin T. P.
Stevens Vernon C.
Triozzi Pierre L.
Calfee Halter & Griswold LLP
Rawlings Stephen L.
The Ohio State University
LandOfFree
Polypeptides and polynucleotides for enhancing immune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptides and polynucleotides for enhancing immune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptides and polynucleotides for enhancing immune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3661403